SG11202110888QA - Bicyclic heteroaryl derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors - Google Patents
Bicyclic heteroaryl derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitorsInfo
- Publication number
- SG11202110888QA SG11202110888QA SG11202110888QA SG11202110888QA SG11202110888QA SG 11202110888Q A SG11202110888Q A SG 11202110888QA SG 11202110888Q A SG11202110888Q A SG 11202110888QA SG 11202110888Q A SG11202110888Q A SG 11202110888QA SG 11202110888Q A SG11202110888Q A SG 11202110888QA
- Authority
- SG
- Singapore
- Prior art keywords
- inhibitors
- bicyclic heteroaryl
- heteroaryl derivatives
- ectonucleotide pyrophosphatase
- pyrophosphatase phosphodiesterase
- Prior art date
Links
- 108010067341 ectonucleotide pyrophosphatase phosphodiesterase 1 Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/027—Organoboranes and organoborohydrides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6503—Five-membered rings
- C07F9/65031—Five-membered rings having the nitrogen atoms in the positions 1 and 2
- C07F9/65038—Five-membered rings having the nitrogen atoms in the positions 1 and 2 condensed with carbocyclic rings or carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6503—Five-membered rings
- C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
- C07F9/65068—Five-membered rings having the nitrogen atoms in positions 1 and 3 condensed with carbocyclic rings or carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962833455P | 2019-04-12 | 2019-04-12 | |
| US201962881111P | 2019-07-31 | 2019-07-31 | |
| PCT/US2020/027700 WO2020210649A1 (en) | 2019-04-12 | 2020-04-10 | Bicyclic heteroaryl derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202110888QA true SG11202110888QA (en) | 2021-10-28 |
Family
ID=70465561
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202110888QA SG11202110888QA (en) | 2019-04-12 | 2020-04-10 | Bicyclic heteroaryl derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US12029744B2 (pt) |
| EP (2) | EP4249070A3 (pt) |
| JP (1) | JP2022526432A (pt) |
| KR (1) | KR20210151873A (pt) |
| CN (1) | CN114040915A (pt) |
| AU (1) | AU2020272034A1 (pt) |
| BR (1) | BR112021020241A2 (pt) |
| CA (1) | CA3136443A1 (pt) |
| DK (1) | DK3952995T3 (pt) |
| ES (1) | ES2960987T3 (pt) |
| FI (1) | FI3952995T3 (pt) |
| HR (1) | HRP20231413T1 (pt) |
| HU (1) | HUE064377T2 (pt) |
| IL (1) | IL286966A (pt) |
| LT (1) | LT3952995T (pt) |
| MX (2) | MX2021012305A (pt) |
| PL (1) | PL3952995T3 (pt) |
| PT (1) | PT3952995T (pt) |
| RS (1) | RS64792B1 (pt) |
| SG (1) | SG11202110888QA (pt) |
| SI (1) | SI3952995T1 (pt) |
| TW (1) | TW202103708A (pt) |
| WO (1) | WO2020210649A1 (pt) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3200318A1 (en) * | 2020-10-30 | 2022-05-05 | 1Cbio, Inc. | Ectonucleotide pyrophosphatase-phosphodiesterase-1 (enpp1) inhibitors and uses thereof |
| AU2022211957B2 (en) * | 2021-01-29 | 2024-05-23 | Txinno Bioscience Inc. | Novel benzotriazole derivative having inhibitory activity against ectonucleotide pyrophosphatase-phosphodiesterase, and use thereof |
| US20240209005A1 (en) * | 2021-03-16 | 2024-06-27 | Riboscience Llc | Bicyclic heteroaryl boronate derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors |
| CN116444544A (zh) * | 2022-01-10 | 2023-07-18 | 中国科学院上海药物研究所 | 苯并咪唑类化合物及其医药用途 |
| WO2024099907A1 (en) * | 2022-11-09 | 2024-05-16 | Boehringer Ingelheim International Gmbh | Cyclic benzimidazole derivatives as cgas inhibitors |
| WO2024149239A1 (zh) * | 2023-01-10 | 2024-07-18 | 上海翊维康医药有限责任公司 | 杂芳环化合物及其制备方法和用途 |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4107288A (en) | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
| US5240938A (en) | 1991-02-13 | 1993-08-31 | Merck & Co., Inc. | Angiotensin II antagonists incorporating a substituted pyridoimidazolyl ring |
| GB9020931D0 (en) | 1990-09-26 | 1990-11-07 | Wellcome Found | Heterocyclic compounds |
| IE914572A1 (en) | 1991-01-17 | 1992-07-29 | Zeneca Ltd | Chemical process |
| IE914573A1 (en) | 1991-01-17 | 1992-07-29 | Ici Plc | Boron compounds |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| DK40192D0 (da) * | 1992-03-26 | 1992-03-26 | Neurosearch As | Imidazolforbindelser, deres fremstilling og anvendelse |
| US5468757A (en) | 1994-01-31 | 1995-11-21 | Eli Lilly And Company | 6-azaindole thromboxane synthase inhibitors |
| AU2583901A (en) | 1999-12-17 | 2001-06-25 | Ariad Pharmaceuticals, Inc. | Proton pump inhibitors |
| MXPA03008560A (es) | 2001-03-22 | 2004-06-30 | Abbot Gmbh & Co Kg | Pirazolopirimidinas como agentes terapeuticos. |
| WO2003000187A2 (en) | 2001-06-21 | 2003-01-03 | Ariad Pharmaceuticals, Inc. | Novel pyrazolo-and pyrrolo-pyrimidines and uses thereof |
| JP2005089334A (ja) | 2003-09-12 | 2005-04-07 | Sumitomo Pharmaceut Co Ltd | ８−ヒドロキシアデニン化合物 |
| WO2007134169A2 (en) | 2006-05-10 | 2007-11-22 | Nuada, Llc | Indole, benzimidazole, and benzolactam boronic acid compounds, analogs thereof and methods of use thereof |
| US20090264384A1 (en) | 2004-11-01 | 2009-10-22 | Nuada, Inc. | Indole, benzimidazole, and benzolactam boronic acid compounds, analogs thereof and methods of use thereof |
| DE102004060699A1 (de) | 2004-12-16 | 2006-06-22 | Ratiopharm Gmbh | Verfahren zur Herstellung von Candesartan |
| PT1833801E (pt) | 2004-12-22 | 2008-08-25 | Algry Quimica S L | Compostos intermediários para a preparação de antagonistas do receptor da angiotensina ii |
| ITMI20050801A1 (it) | 2005-05-03 | 2006-11-04 | Dipharma Spa | Procedimento per la preparazione di telmisartan |
| WO2006125592A2 (en) * | 2005-05-24 | 2006-11-30 | Lek Pharmaceuticals D.D. | Process for the preparation of 2-alkyl-1-((2'-substituted-biphenyl-4-yl)methyl)-imidazole, dihydroimidazole or benzimidazole derivatives |
| US8071609B2 (en) | 2005-08-11 | 2011-12-06 | Ariad Pharmaceuticals, Inc. | Unsaturated heterocyclic derivatives |
| CN100427488C (zh) * | 2005-10-21 | 2008-10-22 | 上海东升新材料有限公司 | 腺嘌呤类衍生物及其合成方法 |
| WO2007081755A2 (en) | 2006-01-09 | 2007-07-19 | Metabasis Therapeutics, Inc. | Indole-benzimidazole and indazole inhibitors of tyrosine phosphatases |
| AU2007269557B2 (en) | 2006-07-07 | 2013-11-07 | Gilead Sciences, Inc. | Modulators of toll-like receptor 7 |
| JP2009242240A (ja) | 2006-08-04 | 2009-10-22 | Mebiopharm Co Ltd | 含ホウ素キナゾリン誘導体 |
| JO3598B1 (ar) * | 2006-10-10 | 2020-07-05 | Infinity Discovery Inc | الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني |
| TWI406850B (zh) | 2007-06-05 | 2013-09-01 | Theravance Inc | 雙效苯并咪唑抗高血壓劑 |
| JP2011506459A (ja) | 2007-12-11 | 2011-03-03 | セラヴァンス， インコーポレーテッド | 抗高血圧剤としての二重作用性ベンゾイミダゾール誘導体およびその使用 |
| RU2547441C2 (ru) * | 2008-03-06 | 2015-04-10 | Анакор Фармасьютикалз, Инк. | Борсодержащие малые молекулы в качестве противовоспалительных агентов |
| PT2565191E (pt) | 2008-05-14 | 2014-12-04 | Astellas Pharma Inc | Derivados do ácido 4-(indol-7- ilcarbonilaminometil)ciclo-hexanocarboxílico como antagonistas de receptores ep4, úteis no tratamento de insuficiência renal crónica ou de nefropatia diabética |
| US20100016609A1 (en) | 2008-07-15 | 2010-01-21 | Wyeth | Methods for the preparation of azole compounds |
| AR075090A1 (es) | 2008-09-29 | 2011-03-09 | Millennium Pharm Inc | Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden. |
| WO2011053247A1 (en) | 2009-10-29 | 2011-05-05 | Agency For Science, Technology And Research | Method for the detection of an analyte by surface enhanced raman spectroscopy (sers) |
| ES2559209T3 (es) | 2010-04-14 | 2016-02-11 | Bristol-Myers Squibb Company | Nuevos activadores de la glucocinasa y métodos de uso de los mismos |
| LT2558577T (lt) | 2010-04-16 | 2019-03-12 | Nuevolution A/S | Bifunkciniai kompleksai ir tokių kompleksų gamybos ir naudojimo būdai |
| EP2670733B1 (en) | 2011-02-01 | 2019-04-10 | The Board of Trustees of the University of Illionis | N-hydroxybenzamide derivatives as hdac inhibitors and therapeutic methods using the same |
| MX2013013331A (es) * | 2011-05-17 | 2014-10-17 | Principia Biopharma Inc | Derivados de azaindol como inhibidores de tirosina-cinasas. |
| PT2776439T (pt) | 2011-11-09 | 2018-11-02 | Janssen Sciences Ireland Uc | Derivados de purina para o tratamento de infeções virais |
| RU2696572C2 (ru) | 2012-03-07 | 2019-08-05 | Инститьют Оф Кансер Ресёрч: Ройял Кансер Хоспитал (Зе) | 3-арил-5-замещенные соединения изохинолин-1-она и их терапевтическое применение |
| MX362341B (es) | 2014-05-01 | 2019-01-11 | Novartis Ag | Compuestos y composiciones como agonistas del receptor tipo toll 7. |
| US10488418B2 (en) | 2014-09-02 | 2019-11-26 | The Regents Of The University Of California | Fluorescence assay for intestinal permeability |
| CA2963772A1 (en) | 2014-10-08 | 2016-04-14 | Thomas Helledays Stiftelse For Medicinsk Forskning | Heterocyclic compounds as dctpp1 modulators |
| WO2016200840A1 (en) | 2015-06-08 | 2016-12-15 | Cleave Biosciences, Inc. | Mono and bicyclic ring boronic acid, ester and salt compounds as inhibitors of p97 complex |
| AU2016304408B2 (en) * | 2015-07-31 | 2019-02-21 | Pfizer Inc., | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as MAGL inhibitors |
| AR108906A1 (es) | 2016-06-29 | 2018-10-10 | Bristol Myers Squibb Co | Heterociclos de biarilmetilo |
| AU2017382294A1 (en) * | 2016-12-22 | 2019-08-01 | Abbvie Inc. | Compositions and methods of enhancing or augmenting type I IFN production |
| CA3047589A1 (en) | 2016-12-22 | 2018-06-28 | Mavupharma, Inc. | Phosphodiesterase inhibitors and methods of microbial treatment |
| US10487084B2 (en) * | 2017-08-16 | 2019-11-26 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor |
| BR112020004209A2 (pt) | 2017-08-31 | 2020-09-01 | Abbvie Inc. | inibidores da ectonucleotide piofosfatase-phosfodiesterase 1 (enpp-1) e uso dos mesmos |
| PL3678668T3 (pl) | 2017-09-08 | 2024-06-03 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibitory enpp1 i ich zastosowanie w leczeniu nowotworu |
| WO2019096113A1 (zh) * | 2017-11-14 | 2019-05-23 | 深圳市塔吉瑞生物医药有限公司 | 一种氘代的含硼的化合物及药物组合物和用途 |
| CN108409767B (zh) | 2018-04-13 | 2020-07-10 | 上海泰坦科技股份有限公司 | 一种杂环联苯硼酸的制备方法 |
| EP3902787A4 (en) | 2018-12-28 | 2022-12-28 | Riboscience LLC | QUINAZOLINE DERIVATIVES USED AS ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 INHIBITORS |
| CN113677350A (zh) | 2019-02-01 | 2021-11-19 | 里兰斯坦福初级大学理事会 | Enpp1抑制剂和调节免疫反应的方法 |
| WO2020191501A1 (en) | 2019-03-27 | 2020-10-01 | Algernon Pharmaceuticals Inc. | Methods and uses of bemithyl and derivatives for treating lung disease, fatty liver disease, and kidney disorders |
| CA3151277A1 (en) | 2019-09-16 | 2021-03-25 | Aten Porus Lifesciences Pvt. Ltd. | 2-amino-s6-substituted thiopurine compounds as inhibitors of the enpp1 protein |
| CN115151253A (zh) | 2019-09-23 | 2022-10-04 | 南京征祥医药有限公司 | 磷酸二酯酶抑制剂及用途 |
| JP2023508978A (ja) | 2019-12-23 | 2023-03-06 | サンフォード バーナム プレビス メディカル ディスカバリー インスティテュート | エクトヌクレオチドピロホスファターゼ／ホスホジエステラーゼ１（ｅｎｐｐ１）モジュレーター及びその使用 |
| MX2022009534A (es) | 2020-02-04 | 2022-11-14 | Stingray Therapeutics Inc | Inhibidores de ectonucleotido pirofosfatasa/fosfofiesterasa 1 (enpp1) y metodos de uso de los mismos. |
| CN115362150A (zh) | 2020-04-09 | 2022-11-18 | 贝达药业股份有限公司 | Enpp1抑制剂及其组合物和用途 |
-
2020
- 2020-04-10 EP EP23187601.2A patent/EP4249070A3/en active Pending
- 2020-04-10 HR HRP20231413TT patent/HRP20231413T1/hr unknown
- 2020-04-10 ES ES20722196T patent/ES2960987T3/es active Active
- 2020-04-10 LT LTEPPCT/US2020/027700T patent/LT3952995T/lt unknown
- 2020-04-10 HU HUE20722196A patent/HUE064377T2/hu unknown
- 2020-04-10 AU AU2020272034A patent/AU2020272034A1/en active Pending
- 2020-04-10 DK DK20722196.1T patent/DK3952995T3/da active
- 2020-04-10 PL PL20722196.1T patent/PL3952995T3/pl unknown
- 2020-04-10 TW TW109112260A patent/TW202103708A/zh unknown
- 2020-04-10 EP EP20722196.1A patent/EP3952995B1/en active Active
- 2020-04-10 RS RS20231040A patent/RS64792B1/sr unknown
- 2020-04-10 JP JP2021559932A patent/JP2022526432A/ja active Pending
- 2020-04-10 KR KR1020217036122A patent/KR20210151873A/ko not_active Application Discontinuation
- 2020-04-10 SI SI202030281T patent/SI3952995T1/sl unknown
- 2020-04-10 US US17/264,684 patent/US12029744B2/en active Active
- 2020-04-10 WO PCT/US2020/027700 patent/WO2020210649A1/en active Application Filing
- 2020-04-10 PT PT207221961T patent/PT3952995T/pt unknown
- 2020-04-10 CN CN202080028332.4A patent/CN114040915A/zh active Pending
- 2020-04-10 SG SG11202110888QA patent/SG11202110888QA/en unknown
- 2020-04-10 BR BR112021020241A patent/BR112021020241A2/pt unknown
- 2020-04-10 CA CA3136443A patent/CA3136443A1/en active Pending
- 2020-04-10 MX MX2021012305A patent/MX2021012305A/es unknown
- 2020-04-10 FI FIEP20722196.1T patent/FI3952995T3/fi active
-
2021
- 2021-10-04 IL IL286966A patent/IL286966A/en unknown
- 2021-10-07 MX MX2023011065A patent/MX2023011065A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112021020241A2 (pt) | 2021-12-07 |
| US20220362266A1 (en) | 2022-11-17 |
| HUE064377T2 (hu) | 2024-03-28 |
| EP3952995A1 (en) | 2022-02-16 |
| JP2022526432A (ja) | 2022-05-24 |
| RS64792B1 (sr) | 2023-11-30 |
| AU2020272034A1 (en) | 2021-10-28 |
| DK3952995T3 (da) | 2023-10-30 |
| TW202103708A (zh) | 2021-02-01 |
| CN114040915A (zh) | 2022-02-11 |
| PL3952995T3 (pl) | 2024-03-11 |
| IL286966A (en) | 2021-12-01 |
| SI3952995T1 (sl) | 2023-12-29 |
| CA3136443A1 (en) | 2020-10-15 |
| US12029744B2 (en) | 2024-07-09 |
| HRP20231413T1 (hr) | 2024-02-16 |
| LT3952995T (lt) | 2023-11-10 |
| MX2021012305A (es) | 2021-11-12 |
| EP3952995B1 (en) | 2023-09-20 |
| EP4249070A2 (en) | 2023-09-27 |
| FI3952995T3 (fi) | 2023-10-26 |
| PT3952995T (pt) | 2023-10-25 |
| ES2960987T3 (es) | 2024-03-07 |
| MX2023011065A (es) | 2023-09-28 |
| WO2020210649A1 (en) | 2020-10-15 |
| EP4249070A3 (en) | 2024-04-17 |
| KR20210151873A (ko) | 2021-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3902787A4 (en) | QUINAZOLINE DERIVATIVES USED AS ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 INHIBITORS | |
| IL286966A (en) | History of bicyclic heteroaryls as ectonucleotide pyrophosphatase phosphodiesterase inhibitors | |
| IL276509A (en) | Heterocyclic compounds as kinase inhibitors | |
| SI3523301T1 (sl) | Substituirane spojine pirazolo(1,5-A)piridina kot inhibitorji RET kinaze | |
| SI3523302T1 (sl) | Substituirane spojine pirazolo(1,5-A)piridina kot inhibitorji ret kinaze | |
| SI3322706T1 (sl) | Substituirane pirazolo(1,5-A)piridinske spojine kot zaviralci ret-kinaze | |
| IL290508A (en) | Heterocyclic compounds as kinase inhibitors | |
| SG11202011299PA (en) | Fused bicyclic compounds useful as ubiquitin-specific peptidase 30 inhibitors | |
| IL269214B (en) | Novel imidazo[5,4-c]quinoline derivatives as lrrk2 inhibitors | |
| SG11202013016YA (en) | Heterocyclic compounds as trk inhibitors | |
| EP3556758C0 (en) | 1,2-DIHYDRO-1,6-NAPHTHYRIDIN-2-ONE DERIVATIVES AS CDK4/6 INHIBITORS | |
| EP3666770A4 (en) | NEW HETEROCYCLIC COMPOUNDS AS CDK8 / 19 INHIBITORS | |
| IL284767A (en) | Heterocyclic compounds as adenosine antagonists | |
| IL289389A (en) | Heterocyclic compounds as kinase inhibitors | |
| IL273443A (en) | Bicyclic compounds for use as RIP1 kinase inhibitors | |
| SG11202109781QA (en) | Uses of phosphodiesterase inhibitors | |
| EP3844166C0 (en) | SUBSTITUTED MACROCYCLES USEFUL AS KINASE INHIBITORS | |
| IL284762A (en) | Heterocyclic compounds as adenosine antagonists | |
| HUE058998T2 (hu) | Heteroaril vegyületek, mint kináz inhibitorok | |
| IL290314A (en) | Quinolines as protein kinase inhibitors | |
| IL291785A (en) | 6,1- Naphthyridine-converted inhibitors of cdk5 | |
| SG11202102015QA (en) | Fused ring derivative used as fgfr4 inhibitor | |
| EA201692227A1 (ru) | Производные сложных аминоэфиров | |
| IL269144A (en) | Pyrrolotriazine derivatives as kinase inhibitors | |
| IL291382A (en) | 2-amino-6s-disubstituted thiopurine compounds as enpp1 protein inhibitors |